

Vadim Le Joncour
Supervisor for doctoral programme, Title of Docent, Postdoctoral Researcher
Neuroscience Center
Faculty Common Matters (Faculty of Medicine)
Doctoral Programme in Biomedicine
Type of address: Postal address.
PL 63 (Haartmaninkatu 8)
00014
Finland
Type of address: Postal address.
Finland
Email: vadim.lejoncour@helsinki.fi
Phone: +358294125579
Mobile: +358504486408



Curriculum vitae

Current Position

2019 – 2022 **Academy of Finland Postdoc Fellow.** *The Mechanistic and Transcriptomic Signature of Gliomas.* With prof. Pirjo Laakkonen. Translational Cancer Medicine Research Program. Faculty of Medicine, University of Helsinki, Finland

Previous Experience

2015 – 2019 **Postdoctoral researcher.** *Research of novel molecular and cellular targets for glioblastoma and brain metastasis treatment.* With prof. Pirjo Laakkonen. Research Programs Unit, Translational Cancer Biology, Faculty of Medicine, University of Helsinki, Finland

2013 – 2014 **University lecturer & research assistant.** Part time University lecturer for undergrad and Master students (201 hrs per annum), and Research assistant, Inserm U982 DC2N lab.

Faculty of Sciences, University of Rouen, France

2010 – 2015 **Ph.D. student.** *Role of the urotensin II receptor in brain tumor progression with Professor Pierrick Gandolfo and Dr. Hélène Castel.* Faculty of Science, University of Rouen, France

Fellowships and Funding

2019 – 2022 **Academy of Finland Postdoc fellowship** for investigating the transcriptomic and mechanistic signature of invasive gliomas, University of Helsinki, Finland (EUR 290,000)

2019 **Personal grant** for postdoctoral research from K. Albin Johansson stiftelse, Finland.

2017 **Faculty of Medicine travel grant** to attend the Primary and Secondary Brain Tumor Conference (Madrid, Spain). University of Helsinki, Finland.

2013 – 2014 **University lecturer and research assistant grant** to complete a Ph.D. University of Rouen, France (EUR 24,000)

2010 – 2013 **Normandy Region selected Thesis Grant** Seine-Maritime, France (EUR 72,000)

Employment

Postdoctoral Researcher

Neuroscience Center
University of Helsinki
Finland
1 May 2023 → present

Title of Docent

Faculty Common Matters (Faculty of Medicine)
University of Helsinki
Finland
24 Mar 2023 → present

Supervisor for doctoral programme

Doctoral Programme in Biomedicine
University of Helsinki
Finland
1 Jan 2015 → present

Research outputs

Comparison of trastuzumab emtansine, trastuzumab deruxtecan, and disitamab vedotin in a multiresistant HER2-positive breast cancer lung metastasis model

Pourjamal, N., Yazdi, N., Halme, A., Le Joncour, V., Laakkonen, P., Saharinen, P., Joensuu, H. & Barok, M., Feb 2024, (E-pub ahead of print) In: Clinical and Experimental Metastasis. 12 p.

Heparin-Derived Theranostic Nanoprobes Overcome the Blood-Brain Barrier and Target Glioma in Murine Model

Samanta, S., Le Joncour, V., Wegrzyniak, O., Rangasami, V. K., Ali-Loytty, H., Hong, T., Selvaraju, R. K., Aberg, O., Hilborn, J., Laakkonen, P., Varghese, O. P., Eriksson, O., Cabral, H. & Oommen, O. P., Jun 2022, In: Advanced Therapeutics. 5, 6, 17 p., 2200001.

Bivalent EGFR-Targeting DARPIn-MMAE Conjugates

Karsten, L., Janson, N., Le Joncour, V., Alam, S., Müller, B., Tanjore Ramanathan, J., Laakkonen, P., Sewald, N. & Mueller, K. M., Mar 2022, In: International Journal of Molecular Sciences. 23, 5, 26 p., 2468.

Peptidotriazolamers Inhibit A beta(1-42) Oligomerization and Cross a Blood-Brain-Barrier Model

Tonali, N., Hericks, L., Schroeder, D. C., Kracker, O., Krzemieniecki, R., Kaffy, J., Le Joncour, V., Laakkonen, P., Marion, A., Ongeri, S., Doderio, V. I. & Sewald, N., Jun 2021, In: ChemPlusChem. 86, 6, p. 840-851 12 p.

Redox responsive Pluronic micelle mediated delivery of functional siRNA: a modular nano-assembly for targeted delivery

Kadekar, S., Nawale, GN., Rangasami, VK., Le Joncour, V., Laakkonen, P., Hilborn, J., Varghese, OP. & Oommen, OP., Jun 2021, In: Biomaterials Science. 9, 11, p. 3939-3944 6 p.

Circumventing Drug Treatment? Intrinsic Lethal Effects of Polyethyleneimine (PEI)-Functionalized Nanoparticles on Glioblastoma Cells Cultured in Stem Cell Conditions

Prabhakar, N., Merisaari, J., Le Joncour, V., Peurla, M., Sen Karaman, D., Casals, E., Laakkonen, P., Westermarck, J. & Rosenholm, J. M., 27 May 2021, In: Cancers. 13, 11, 19 p., 2631.

CD109-GP130 interaction drives glioblastoma stem cell plasticity and chemoresistance through STAT3 activity

Filppu, P., Ramanathan, J. T., Granberg, K. J., Gucciardo, E., Haapasalo, H., Lehti, K., Nykter, M., Le Joncour, V. & Laakkonen, P., 10 May 2021, In: JCI INSIGHT. 6, 9, 21 p., 141486.

Prostate-specific membrane antigen expression in the vasculature of primary lung carcinomas associates with faster metastatic dissemination to the brain

Ramanathan, J. T., Lehtipuro, S., Sihto, H., Tovari, J., Reiniger, L., Teglas, V., Moldvay, J., Nykter, M., Haapasalo, H., Le Joncour, V. & Laakkonen, P., Jun 2020, In: Journal of Cellular and Molecular Medicine. 24, 12, p. 6916-6927 12 p.

Prolyl 4-hydroxylase subunit alpha 1 (P4HA1) is a biomarker of poor prognosis in primary melanomas and its depletion inhibits melanoma cell invasion and disrupts tumor blood vessel walls

Eriksson, J., Le Joncour, V., Jahkola, T., Juteau, S., Laakkonen, P., Saksela, O. & Hölttä, E., Apr 2020, In: Molecular oncology. 14, 4, p. 742-762 21 p.

ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer

Barok, M., Le Joncour, V., Martins, A., Isola, J., Salmikangas, M., Laakkonen, P. & Joensuu, H., 2020, In: Cancer Letters. 473, p. 156-163 8 p.

Monotherapy efficacy of blood-brain barrier permeable small molecule reactivators of protein phosphatase 2A in glioblastoma

Merisaari, J., Denisova, O., Doroszko, M., Le Joncour, V., Johansson, P., Leenders, W. P. J., Kastrinsky, D. B., Zaware, N., Narla, G., Laakkonen, P., Nelander, S., Ohlmeyer, M. & Westermarck, J., 2020, In: Brain communications. 2, 1, 12 p., 02.

A Novel Anti-HER2 Antibody-Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine

Le Joncour, V., Martins, A., Puhka, M., Isola, J., Salmikangas, M., Laakkonen, P., Joensuu, H. & Barok, M., Oct 2019, In: Molecular Cancer Therapeutics. 18, 10, p. 1721-1730 10 p.

Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization

Le Joncour, V., Filppu, P., Hyvönen, M., Holopainen, M., Turunen, S. P., Sihto, H., Burghardt, I., Joensuu, H., Tynnen, O., Jääskeläinen, J., Weller, M., Lehti, K., Käkälä, R. & Laakkonen, P., Jun 2019, In: EMBO molecular medicine. 11, 6, 21 p., 9034.

Octreotide Conjugates for Tumor Targeting and Imaging

Figueras, E., Martins, A., Borbely, A., Le Joncour, V., Cordella, P., Perego, R., Modena, D., Pagani, P., Esposito, S., Auciello, G., Frese, M., Gallinari, P., Laakkonen, P., Steinkuhler, C. & Sewald, N., May 2019, In: Pharmaceutics. 11, 5, 14 p., 220.

Predicting In Vivo Payloads Delivery using a Blood-brain Tumor-barrier in a Dish

Le Joncour, V., Karaman, S. & Laakkonen, P. M., 16 Apr 2019, In: Journal of Visualized Experiments. 146, 12 p., 59384.

Seek & Destroy, use of targeting peptides for cancer detection and drug delivery

Le Joncour, V. & Laakkonen, P., 1 Jun 2018, In: Bioorganic & Medicinal Chemistry. 26, 10, p. 2797-2806 10 p.

Targeting peptides, a Swiss-army knife against cancer

Le Joncour, V. J. M. & Laakkonen, P., 2018, *Amino Acids, Peptides and Proteins*. Ryadnov, M. & Hudecz, F. (eds.). Royal Society of Chemistry, Vol. 42. p. 281-320 40 p.

Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression

Eriksson, J., Le Joncour, V., Nummela, P., Jahkola, T., Virolainen, S., Laakkonen, P., Saksela, O. & Hölttä, E., 22 Mar 2016, In: Oncotarget. 7, 12, p. 15065-15092 28 p.

Activities

Finnish Brain Tumor Research Association Annual Meeting: FiBTRA 2019

Pirjo Laakkonen (Member of organizing committee), Vadim Le Joncour (Member of organizing committee) & Pauliina Filppu (Member of organizing committee)
31 Oct 2019 → 1 Nov 2019

Oral presentation to FiBTRA 2017

Vadim Le Joncour (Speaker)
27 Oct 2017

Finnish Brain Tumor Research Association Annual Meeting

Vadim Le Joncour (Member of organizing committee), Pirjo Maarit Laakkonen (Member of organizing committee), Pauliina Irmeli Filppu (Attendee), Jayendrakishore Tanjore Ramanathan (Attendee), Abiodun Olanrewaju Ayo (Attendee), Seppo Ylä-Herttua (Speaker: Keynote) & Jukka Westermarck (Member of organizing committee)
1 Nov 2016 → 2 Nov 2016

Presentation to the Magic Bullet Network Meeting

Vadim Le Joncour (Speaker)
19 Jul 2016

Prizes

FiBTRA 2019 selected talk

Le Joncour, Vadim (Recipient), 1 Nov 2019

K. Albin Johansson foundation

Le Joncour, Vadim (Recipient), 11 Dec 2019

Press/Media

Cover of the EMBO Molecular Medicine journal

Vadim Le Joncour

07/06/2019

1 item of Media coverage

Exploiting a Chink in the Armor of Brain Tumor Cells

Pirjo Laakkonen & Vadim Le Joncour

13/05/2019

1 item of Media coverage

Researchers discover the Achilles' heel of an aggressive brain cancer

Harri Sihto, Heikki Joensuu, Pirjo Laakkonen & Vadim Le Joncour

10/05/2019 → 13/05/2019

8 items of Media coverage

-UNIVERSITY OF HELSINKI: Researchers discover the Achilles' heel of an aggressive brain cancer - could antihistamine be a potential aid in defeating cancerous cells?

Harri Sihto, Heikki Joensuu, Pirjo Laakkonen & Vadim Le Joncour

13/05/2019

1 item of Media coverage